Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
News and updates for Numinus Wellness Inc. (NUMIF) focus on its activities as a mental health care company centered on safe, evidence-based psychedelic-assisted therapies. Company announcements consistently describe efforts to advance behavioral health treatments through clinical trial research, practitioner training and technology-driven support for clinic-based delivery of psychedelic-assisted therapy.
Readers of the Numinus news feed can expect coverage of financial results, including quarterly updates that discuss revenue trends, gross margin, operating expenditures and cash position. These releases often highlight performance at Cedar Clinical Research, where Numinus manages clinical trials and provides research services for drug sponsors, as well as metrics related to its practitioner training business.
Corporate news also includes strategic and organizational developments. Numinus has reported the sale of its U.S. clinic network, the wind-down of non-operating subsidiaries through bankruptcy, and leadership changes such as the appointment of a new Chief Executive Officer and transitions in the Chief Financial Officer role. Additional updates describe accreditation milestones for its Psychedelic-Assisted Therapy Training Program in jurisdictions such as Oregon and Colorado, and engagements like Cedar Clinical Research’s participation in a Phase 3 multinational trial for CYB003 targeting Major Depressive Disorder.
Regulatory and capital markets developments are another recurring theme. Numinus has issued news about a cease trade order affecting its shares, its application to the British Columbia Securities Commission for revocation, and its stated intention to pursue relisting on another reputable exchange once conditions permit. For investors and observers, following NUMIF news provides insight into the company’s operational focus, restructuring steps, regulatory progress and evolving role in the psychedelic-assisted therapy ecosystem.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) will participate in Maxim Group's 2022 Virtual Growth Conference from March 28-30, 2022. A presentation by Founder and CEO Payton Nyquvest will be available on-demand starting March 28 at 9:00 a.m. ET. Interested participants can register here. Numinus focuses on innovative mental health care and evidence-based psychedelic therapies aimed at addressing conditions like depression and anxiety.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) has received approval from the Public Health Agency of Canada for a Containment Level 2 license at its Numinus Bioscience lab. This enhancement enables advanced research on natural psychedelics, focusing on studies involving Psilocybe mushrooms and their effects on the human body. The license will facilitate tests that support innovative intellectual property development and revenue generation through contract research services. The company aims to advance its psychedelic research initiatives and enhance the accessibility of psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has received approval from Health Canada to expand its research license, allowing the study of Ayahuasca and San Pedro at its Numinus Bioscience facility. This expansion positions Numinus as a key player in psychedelic research, complementing ongoing studies on Psilocybe species. The renewed license permits work with several botanical materials essential for Ayahuasca, including Banisteriopsis caapi and Psychotria viridis. Numinus aims to deepen the scientific understanding of these compounds' therapeutic applications.
On February 28, 2022, Numinus Wellness announced the results from its Annual General and Special Meeting of Shareholders, with 12.73% of common shares represented. Five directors were elected, including Payton Nyquvest and Edwin Garner, with approval rates ranging from 74.27% to 96.65%. Shareholders also approved resolutions regarding the number of directors, the appointment of auditors Davidson & Company LLP, and the Omnibus Equity Incentive Plan. For further details, the Management Information Circular is available on SEDAR.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will participate in the AAAS 2022 Annual Meeting from February 17-20, 2022. Dr. Devon Christie will discuss frontier psychedelic research, alongside notable scientists such as Dr. Robin Carhart-Harris and Dr. Frederick Barrett. The session, titled "Psychedelic Research: Moving Beyond the Social and Political Stigma," is scheduled for February 19 at 3:00 p.m. ET. Additionally, a media availability session is set for February 20 at 9:00 a.m. ET. Numinus focuses on innovative mental health treatments, emphasizing safe, evidence-based psychedelic therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announces the formation of a new Bioscience Advisory Board with the appointment of three experts: Graham Pechenik, Dr. Paul Spagnuolo, and Dr. Cory Harris. These appointments aim to enhance Numinus' intellectual property strategy and strengthen its project pipeline in psychedelic-assisted therapies. The advisors bring extensive backgrounds in patent law, nutraceuticals, and ethnobotany, reflecting Numinus' commitment to developing innovative mental health solutions and advancing its clinical trial activities.
Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) has announced its move to the OTCQX® Best Market in the U.S., effective January 27, 2022. This transition from the Pink market aims to enhance visibility and accessibility for U.S. investors, as the company expands its network of Numinus Health wellness clinics. The OTCQX Market is tailored for established companies meeting specific financial and governance standards, which may boost Numinus' profile within the U.S. investment community.
Numinus Wellness (TSX: NUMI) (OTC: NUMIF), a leader in mental health care, announced its participation in Citi's Psychedelic Drug Call Series on February 2, 2022. The event will feature a fireside chat between Payton Nyquvest, Founder and CEO of Numinus, and Neena Bitritto-Garg, Citi's Biotech analyst, at 10:00 a.m. ET. Numinus focuses on psychedelic-assisted therapies to improve mental health outcomes for conditions like depression and anxiety. More details are available on Numinus' website.
Numinus Wellness reported fiscal Q1 2022 results, showcasing a robust cash position of $53.9 million and a significant 245% year-over-year revenue growth to $0.8 million. The company achieved a gross profit of $50,965, marking a 6.5% gross margin. Notable operational advancements include a clinical trial application for its proprietary psilocybe extract and the initiation of a MAPS-sponsored MDMA-Assisted Therapy study for PTSD. Numinus continues to expand its wellness clinic network, enhancing its capability to provide psychedelic-assisted psychotherapy services.
Numinus Wellness reported strong financial results for Q4 and FY 2021, with revenues increasing by 81% year-over-year to $0.5 million in Q4 and 72% to $1.5 million for the full year. The company boasts a robust cash position of $59.2 million. Despite a gross profit of $31,818 for Q4, Numinus incurred a quarterly loss of $7.8 million, which included a $1.6 million non-cash impairment charge. Key initiatives include the acquisition of the Neurology Centre of Toronto and the launch of clinical trials for psilocybin and MDMA therapies.
FAQ
What is the current stock price of Numinus Wellness (NUMIF)?
What is the market cap of Numinus Wellness (NUMIF)?
